# Truveta’s Study on Tirzepatide vs Semaglutide for Weight Loss – Truveta conducted a real-world data study comparing the effectiveness of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss. – The study, recently published in JAMA Internal Medicine, aimed to provide insights into the real-world effectiveness of these two medications. – Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, while semaglutide is a once-weekly GLP-1 receptor agonist. ## Key Findings – The study showed that patients receiving tirzepatide experienced a greater percentage of body weight loss compared to those on semaglutide. – Participants on tirzepatide also had a higher response rate in achieving a 5% weight loss compared to semaglutide. – The results of this study could potentially influence treatment decisions for individuals seeking pharmacological interventions for weight management. ### Takeaway Real-world studies like Truveta’s provide valuable insights into the comparative effectiveness of weight loss medications, helping healthcare providers make informed decisions for their patients. Contact Mindful Evolution for personalized weight loss strategies and support on your weight loss journey. Weight Loss Disclaimer: Individual results may vary. Our telehealth services are available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.